NSE: ALKEM · 22 October 2026
- Alkem Laboratories Ltd. (ALKEM) ended the trading session on October 22, 2026, virtually unchanged, down 0.03% to close at ₹5,013.50 compared to its previous close of ₹5,015.00. The stock experienced an initial gap-down of 1.67%, touching an intraday low of ₹4,811.00—matching its 52-week low—before recovering to an intraday high of ₹5,015.00.
- Alkem Laboratories announced that its Audit Committee approved the initiation of a forensic audit by Grant Thornton Bharat LLP. The review examines facts surrounding a recent incident involving alleged misappropriation of funds by a former employee and aims to determine the root cause and recommend corrective measures.
- Trading volume was 0.34 times the 20-day average daily volume.
Why is Alkem Laboratories share price falling on 22 October 2026?
Alkem Laboratories Ltd. (ALKEM) ended the trading session on October 22, 2026, virtually unchanged, down 0.03% to close at ₹5,013.50 compared to its previous close of ₹5,015.00. The stock experienced an initial gap-down of 1.67%, touching an intraday low of ₹4,811.00—matching its 52-week low—before recovering to an intraday high of ₹5,015.00.
The broader market witnessed downward pressure as the benchmark Nifty fell 0.88%, while the Nifty Pharma sector index edged down by 0.07%. Alkem's marginal decline outperformed the broader market pullback while staying closely aligned with its pharmaceutical sector peers. Over short-term and medium-term horizons, the stock has posted returns of -3.61% over the past 5 days and -5.96% over the past 20 trading sessions.
Recent corporate developments show that the company's Audit Committee approved the initiation of a forensic audit by Grant Thornton Bharat LLP following an incident involving alleged fund misappropriation by a former employee.
49,335 shares traded by 22 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.46 lakh shares (0.34 times). The five-day average daily volume was 1.35 lakh shares. Separately, the NSE report for 22 October 2026 showed 16,573 shares delivered, representing 33.59% of that day’s traded volume. The same report recorded 11,559 trades.
The stock recovered from an opening gap-down that touched its 52-week low of ₹4,811 to close virtually unchanged amid below-average cash volumes. In the absence of a direct same-day operational catalyst, the price action reflects routine market absorption and technical positioning following recent downward pressure.
Latest Company Developments
Alkem Laboratories announced that its Audit Committee approved the initiation of a forensic audit by Grant Thornton Bharat LLP. The review examines facts surrounding a recent incident involving alleged misappropriation of funds by a former employee and aims to determine the root cause and recommend corrective measures.
It provides transparency regarding internal governance reviews and remediation steps following suspected irregularities.
The company announced the launch of NeuCeno (cenobamate) in India for the treatment of partial-onset seizures in adult patients. This addition expands Alkem's specialty and chronic therapeutics portfolio.
It highlights execution in expanding specialized pharmaceutical product offerings in domestic markets.
Alkem Laboratories informed exchanges about the appointment of Mr. Laxmikant Tiwari as Senior Management Personnel for operations and Mr. Nilesh Vartak for supply chain leadership, effective October 12, 2026.
These appointments strengthen operational and supply chain executive leadership continuity.
a press release dated September 16, 2026, titled "Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.".
Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company effective. October 12, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.
The filing reported 29 MF/UTI holders.
Research & Brokerage Views
Maintained a Neutral rating following Q1 earnings results while updating the target price to ₹5,770.
Historical Bulk / Block Deals
What to Watch Next
- Progress and findings from the Grant Thornton Bharat LLP forensic audit
- Delivery percentages and cash trading volumes relative to the 20-day average
- Performance and market adoption of newly launched specialty products like NeuCeno
- Execution of supply chain and operational strategies under newly appointed senior management
Other Dated Coverage
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026 — 14 October 2026
- Alkem Laboratories in Focus After Senior Management Appointments | 13 October 2026 — 13 October 2026
- Alkem Laboratories Share Price Today: Why ALKEM Is Rising 1.11% | 7 October 2026 — 7 October 2026
More Alkem Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Alkem Laboratories company news?
Alkem Laboratories announced that its Audit Committee approved the initiation of a forensic audit by Grant Thornton Bharat LLP. The review examines facts surrounding a recent incident involving alleged misappropriation of funds by a former employee and aims to determine the root cause and recommend corrective measures.
How strong was Alkem Laboratories’s trading volume?
49,335 shares traded, 0.34 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.